101 results on '"Verhey, Frans R. J."'
Search Results
2. Improving the Lives of People with Dementia through Technology
- Author
-
Orrell, Martin, primary, Oliveira, Déborah, additional, McDermott, Orii, additional, Verhey, Frans R. J., additional, Dassen, Fania C. M., additional, and Dröes, Rose-Marie, additional
- Published
- 2022
- Full Text
- View/download PDF
3. Digital diaries to understand and support everyday life in ageing and dementia
- Author
-
Bartels, Sara Laureen, primary, van Knippenberg, Rosalia J.M., additional, Malinowsky, Camilla Walles, additional, de Vugt, Marjolein, additional, and Verhey, Frans R. J., additional
- Published
- 2022
- Full Text
- View/download PDF
4. Conclusion
- Author
-
Dröes, Rose-Marie, primary, Orrell, Martin, additional, and Verhey, Frans R. J., additional
- Published
- 2022
- Full Text
- View/download PDF
5. An introduction to the INDUCT programme
- Author
-
Orrell, Martin, primary, Oliveira, Déborah, additional, McDermott, Orii, additional, Verhey, Frans R. J., additional, and Dröes, Rose-Marie, additional
- Published
- 2022
- Full Text
- View/download PDF
6. The unique training programme of INDUCT
- Author
-
Dassen, Fania C.M., primary, Bartels, Sara Laureen, additional, Christie, Hannah, additional, Van den Block, Lieve, additional, de Vugt, Marjolein, additional, and Verhey, Frans R. J., additional
- Published
- 2022
- Full Text
- View/download PDF
7. Implementing eHealth interventions in dementia care
- Author
-
Christie, Hannah, primary, Boots, Lizzy M. M., additional, Tange, Huibert J., additional, Verhey, Frans R. J., additional, and de Vugt, Marjolein, additional
- Published
- 2022
- Full Text
- View/download PDF
8. Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
- Author
-
Visser, Pieter Jelle, Reus, Lianne M., Gobom, Johan, Jansen, Iris, Dicks, Ellen, van der Lee, Sven J., Tsolaki, Magda, Verhey, Frans R. J., Popp, Julius, Martinez-Lage, Pablo, Vandenberghe, Rik, Lleó, Alberto, Molinuevo, José Luís, Engelborghs, Sebastiaan, Freund-Levi, Yvonne, Froelich, Lutz, Sleegers, Kristel, Dobricic, Valerija, Lovestone, Simon, Streffer, Johannes, Vos, Stephanie J. B., Bos, Isabelle, Smit, August B., Blennow, Kaj, Scheltens, Philip, Teunissen, Charlotte E., Bertram, Lars, Zetterberg, Henrik, and Tijms, Betty M.
- Published
- 2022
- Full Text
- View/download PDF
9. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
- Author
-
Visser, Pieter Jelle, Reus, Lianne M., Gobom, Johan, Jansen, Iris, Dicks, Ellen, van der Lee, Sven J., Tsolaki, Magda, Verhey, Frans R. J., Popp, Julius, Martinez-Lage, Pablo, Vandenberghe, Rik, Lleó, Alberto, Molinuevo, José Luís, Engelborghs, Sebastiaan, Freund-Levi, Yvonne, Froelich, Lutz, Sleegers, Kristel, Dobricic, Valerija, Lovestone, Simon, Streffer, Johannes, Vos, Stephanie J. B., Bos, Isabelle, Smit, August B., Blennow, Kaj, Scheltens, Philip, Teunissen, Charlotte E., Bertram, Lars, Zetterberg, Henrik, and Tijms, Betty M.
- Published
- 2022
- Full Text
- View/download PDF
10. Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study
- Author
-
Bakker, Lieke, Ramakers, Inez H. G. B., van Boxtel, Martin P. J., Schram, Miranda T., Stehouwer, Coen D. A., van der Kallen, Carla J. H., Dagnelie, Pieter C., van Greevenbroek, Marleen M. J., Wesselius, Anke, Midttun, Øivind, Ueland, Per M., Verhey, Frans R. J., Eussen, Simone J. P. M., and Köhler, Sebastian
- Published
- 2021
- Full Text
- View/download PDF
11. Association of tear fluid amyloid and tau levels with disease severity and neurodegeneration
- Author
-
Gijs, Marlies, Ramakers, Inez H. G. B., Visser, Pieter Jelle, Verhey, Frans R. J., van de Waarenburg, Marjo P. H., Schalkwijk, Casper G., Nuijts, Rudy M. M. A., and Webers, Carroll A. B.
- Published
- 2021
- Full Text
- View/download PDF
12. Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions
- Author
-
Reus, Lianne M., Jansen, Iris E., Mol, Merel O., van Ruissen, Fred, van Rooij, Jeroen, van Schoor, Natasja M., Tesi, Niccolò, Reinders, Marcel J. T., Huisman, Martijn A., Holstege, Henne, Visser, Pieter Jelle, de Boer, Sterre C. M., Hulsman, Marc, Ahmad, Shahzad, Amin, Najaf, Uitterlinden, Andre G., Ikram, Arfan, van Duijn, Cornelia M., Seelaar, Harro, Ramakers, Inez H. G. B., Verhey, Frans R. J., van der Lugt, Aad, Claassen, Jurgen A. H. R., Jan Biessels, Geert, De Deyn, Peter Paul, Scheltens, Philip, van der Flier, Wiesje M., van Swieten, John C., Pijnenburg, Yolande A. L., and van der Lee, Sven J.
- Published
- 2021
- Full Text
- View/download PDF
13. Determinants of quality of life in family caregivers in MCI: a comparison with mild dementia
- Author
-
Tan, Eva Y. L., primary, Janssen, Niels, additional, Handels, Ron, additional, Ramakers, Inez H. G. B., additional, Verhey, Frans R. J., additional, van der Flier, Wiesje M., additional, Melis, René J. F., additional, Olde Rikkert, Marcel G. M., additional, Schols, Jos M. G. A., additional, and de Vugt, Marjolein E., additional
- Published
- 2023
- Full Text
- View/download PDF
14. Contributions of modifiable risk factors to increased dementia risk in depression.
- Author
-
Geraets, Anouk F. J., Leist, Anja K., Deckers, Kay, Verhey, Frans R. J., Schram, Miranda T., and Köhler, Sebastian
- Subjects
DEMENTIA risk factors ,DEMENTIA prevention ,STRUCTURAL equation modeling ,CONFIDENCE intervals ,AGE distribution ,RISK assessment ,SEX distribution ,INCOME ,MENTAL depression ,CENTER for Epidemiologic Studies Depression Scale ,DESCRIPTIVE statistics ,RESEARCH funding ,LONGITUDINAL method ,EDUCATIONAL attainment ,MIDDLE age - Abstract
Background: Individuals with depression have an increased dementia risk, which might be due to modifiable risk factors for dementia. This study investigated the extent to which the increased risk for dementia in depression is explained by modifiable dementia risk factors. Methods: We used data from the English Longitudinal Study of Ageing (2008–2009 to 2018–2019), a prospective cohort study. A total of 7460 individuals were included [mean(standard deviation) age, 65.7 ± 9.4 years; 3915(54.7%) were women]. Depressive symptoms were assessed with the Center for Epidemiologic Studies Depression Scale-8 (score ≥3) or self-reported doctor's diagnosis. Ten modifiable risk factors for dementia were combined in the 'LIfestyle for BRAin health' (LIBRA) score. Dementia was determined by physician diagnosis, self-reported Alzheimer's disease or the shortened version of the Informant Questionnaire on Cognitive Decline in the Elderly (average score ≥3.38). Structural equation modelling was used to test mediation of LIBRA score. Results: During 61 311 person-years, 306 individuals (4.1%) developed dementia. Participants aged 50–70 years with depressive symptoms had higher LIBRA scores [difference(s.e.) = 1.15(0.10)] and a 3.59 times increased dementia risk [HR(95% CI) = 3.59(2.20–5.84)], adjusted for age, sex, education, wealth and clustering at the household level. In total, 10.4% of the dementia risk was mediated by differences in LIBRA score [indirect effect: HR = 1.14(1.03–1.26)], while 89.6% was attributed to a direct effect of depressive symptoms on dementia risk [direct effect: HR = 3.14(2.20–5.84)]. Conclusions: Modifiable dementia risk factors can be important targets for the prevention of dementia in individuals with depressive symptoms during midlife. Yet, effect sizes are small and other aetiological pathways likely exist. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Determinants of quality of life in family caregivers in MCI:a comparison with mild dementia
- Author
-
Tan, Eva Y. L., Janssen, Niels, Handels, Ron, Ramakers, Inez H. G. B., Verhey, Frans R. J., van der Flier, Wiesje M., Melis, René J. F., Olde Rikkert, Marcel G. M., Schols, Jos M. G. A., and de Vugt, Marjolein E.
- Abstract
Objectives: The aim of the current study was to investigate the health-related quality of life (HRQol) of the family caregiver in MCI, explore possible determinants and study possible differences with mild dementia. Methods: This secondary data analysis included 145 persons with MCI and 154 persons with dementia and their family caregivers from two Dutch cohort studies. HRQoL was measured with the VAS of the EuroQol-5D-3L version. Regressions analyses were conducted to examine potential demographic and clinical determinants of the caregiver’s HRQoL. Results: The mean EQ5D-VAS in family caregivers of persons with MCI was 81.1 (SD 15.7), and did not significantly differ from family caregivers in mild dementia (81.9 (SD 13.0)). In MCI, patient measurements were not significantly associated with caregiver mean EQ5D-VAS. Concerning caregiver characteristics, being a spouse and a lower educational level were associated with a lower mean EQ5D-VAS (in a multiple linear regression model: unstandardized B −8.075, p = 0.013 and unstandardized B −6.162, p = 0.037 resp.). In mild dementia, the NPI item irritability showed an association with caregiver EQ5D-VAS in bivariate linear regression analyses. Conclusion: Results indicate that especially family caregiver characteristics seem to influence family caregiver HRQoL in MCI. Future research should include other potential determinants such as burden, coping strategies and relationship quality.
- Published
- 2023
16. Conclusion:Best Practice Guidance human interaction with technology in dementia
- Author
-
Dröes, Rose-Marie, Orrell, Martin, Verhey, Frans R. J., Psychiatry, APH - Mental Health, APH - Methodology, and APH - Aging & Later Life
- Published
- 2022
17. Distinct Patterns Link the BDNF Val66Met Polymorphism to Alzheimer's Disease Pathology
- Author
-
Riphagen, Joost M, van Hooren, Roy W E, Kenis, Gunter, Verhey, Frans R J, Jacobs, Heidi I L, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Psychiatrie & Neuropsychologie, Psychology 1, Psychology 4, MUMC+: MA Niet Med Staf Psychiatrie (9), RS: MHeNs - R3 - Neuroscience, Basic Neuroscience 1, and MUMC+: MA Med Staf Spec Psychiatrie (9)
- Subjects
INTERLEUKIN-6 ,BETA ,interleukin 6 ,tau Proteins ,brain-derived neurotropic growth factor ,phosphorylated tau ,APOLIPOPROTEIN-E ,MECHANISMS ,NEUROINFLAMMATION ,Apolipoproteins E ,Alzheimer Disease ,Humans ,Cognitive Dysfunction ,Inflammation ,Amyloid beta-Peptides ,General Neuroscience ,Brain-Derived Neurotrophic Factor ,CYTOKINES ,ASSOCIATION ,General Medicine ,Alzheimer's disease ,IMPAIRMENT ,amyloid-beta ,Peptide Fragments ,Psychiatry and Mental health ,Clinical Psychology ,COGNITIVE DECLINE ,Geriatrics and Gerontology ,Biomarkers ,NEUROTROPHIC FACTOR - Abstract
The brain-derived neurotropic growth factor (BDNF) gene has been linked to dementia, inflammation, and Apolipoprotein E (APOE) ɛ4 status. We used cerebrospinal fluid (CSF) amyloid-β (Aβ)42 and phosphorylated tau (p-tau) to investigate associations with BDNF polymorphisms and modifications by APOE ɛ4 or inflammation in a memory clinic population (n = 114; subjective cognitive decline, mild cognitive impairment, Alzheimer’s disease). We found distinct pathways to Alzheimer’s disease pathology: Val-Met displayed lower CSF-Aβ42 in APOE ɛ4+ carriers, independent of p-tau, while Val-Val displayed greater p-tau at higher IL-6 and sub-threshold Aβ42. This may contribute to resolving some inconsistencies in the BDNF literature and provide possible inroads to specific Aβ and tau interventions depending on BDNF polymorphism.
- Published
- 2022
18. Towards age‐friendly municipalities: What are municipalities doing to support their ageing population with mental health problems?
- Author
-
Schichel, Mignon C. P., Veenstra, Marja Y., Kempen, Gertrudis I. J. M., de Vugt, Marjolein E., and Verhey, Frans R. J.
- Subjects
MENTAL illness ,CITIES & towns ,MENTAL age ,POPULATION aging ,COMMUNITIES - Abstract
Municipalities in Western Europe have increasingly gained a responsibility to support their populations' healthy ageing, but are they ready to do so? In this case study, we are looking into the awareness, attitudes, capacities and mandates of 33 neighboring Belgian, Dutch, and German municipalities to support ageing people, and especially people with dementia, people with late‐life depression and informal caregivers. As part of the Senior Friendly Communities Interreg project, we conducted semi‐structured interviews with municipal policymakers and relevant stakeholders from May 2017 to January 2018. The results show that dementia was a more salient theme in municipality policies than depression; that informal caregivers were considered important but difficult for municipalities to identify; that there was a difference between how embedded these health themes were in policies versus in practice; and lastly, that conducting this assessment turned out to act as an intervention itself. We discuss the similarities and differences between the regions, and the context that needs to be taken into account for municipalities when becoming more age‐friendly. These results do not only provide an insight into the status quo of the participating municipalities with regard to becoming more age‐friendly but can provide a starting point for further development of policies in this area. Key points: The Senior Friendly Communities project stimulates age‐friendly municipality policies for people with dementia, people with late‐life depression, and informal caregivers.This paper describes the results of interviews with officials from municipalities in the Meuse‐Rhine Euroregion who participated in the Senior Friendly Communities project.The results indicate that dementia is a more salient topic in municipality policies than depression.Informal caregivers are regarded as difficult to identify for municipalities.The support of healthy ageing differs between policies and practice.Conducting assessments of municipal health policies acted as an intervention itself. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. Towards age‐friendly municipalities: What are municipalities doing to support their ageing population with mental health problems?
- Author
-
Schichel, Mignon C. P., primary, Veenstra, Marja Y., additional, Kempen, Gertrudis I. J. M., additional, Vugt, Marjolein E., additional, and Verhey, Frans R. J., additional
- Published
- 2022
- Full Text
- View/download PDF
20. Screening for neuropsychological assessment in the diagnostics of neurocognitive disorder
- Author
-
Ramakers, Inez H. G. B., primary and Verhey, Frans R. J., additional
- Published
- 2022
- Full Text
- View/download PDF
21. Worry Modifies the Relationship between Locus Coeruleus Activity and Emotional Mnemonic Discrimination
- Author
-
Pagen, Linda H. G., primary, Poser, Benedikt A., additional, van Boxtel, Martin P. J., additional, Priovoulos, Nikos, additional, van Hooren, Roy W. E., additional, Verhey, Frans R. J., additional, and Jacobs, Heidi I. L., additional
- Published
- 2022
- Full Text
- View/download PDF
22. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum
- Author
-
Jansen, Willemijn J, Janssen, Olin, von Arnim, Christine, Marquié, Marta, Martinez-Lage, Pablo, Maserejian, Nancy, Mattsson, Niklas, de Mendonça, Alexandre, Meyer, Philipp T, Miller, Bruce L, Minatani, Shinobu, Mintun, Mark A, Mok, Vincent C T, Baiardi, Simone, Molinuevo, Jose Luis, Morbelli, Silvia Daniela, Morris, John C, Mroczko, Barbara, Na, Duk L, Newberg, Andrew, Nobili, Flavio, Nordberg, Agneta, Olde Rikkert, Marcel G M, de Oliveira, Catarina Resende, Baldeiras, Ines, Olivieri, Pauline, Orellana, Adela, Paraskevas, George, Parchi, Piero, Pardini, Matteo, Parnetti, Lucilla, Peters, Oliver, Poirier, Judes, Popp, Julius, Prabhakar, Sudesh, Barthel, Henryk, Rabinovici, Gil D, Ramakers, Inez H, Rami, Lorena, Reiman, Eric M, Rinne, Juha O, Rodrigue, Karen M, Rodríguez-Rodriguez, Eloy, Roe, Catherine M, Rosa-Neto, Pedro, Rosen, Howard J, Bateman, Randall J, Rot, Uros, Rowe, Christopher C, Rüther, Eckart, Ruiz, Agustín, Sabri, Osama, Sakhardande, Jayant, Sánchez-Juan, Pascual, Sando, Sigrid Botne, Santana, Isabel, Sarazin, Marie, Van Berckel, Bart, Scheltens, Philip, Schröder, Johannes, Selnes, Per, Seo, Sang Won, Silva, Dina, Skoog, Ingmar, Snyder, Peter J, Soininen, Hilkka, Sollberger, Marc, Sperling, Reisa A, Binette, Alexa Pichet, Spiru, Luisa, Stern, Yaakov, Stomrud, Erik, Takeda, Akitoshi, Teichmann, Marc, Teunissen, Charlotte E, Thompson, Louisa I, Tomassen, Jori, Tsolaki, Magda, Vandenberghe, Rik, Blennow, Kaj, Verbeek, Marcel M, Verhey, Frans R J, Villemagne, Victor, Villeneuve, Sylvia, Vogelgsang, Jonathan, Waldemar, Gunhild, Wallin, Anders, Wallin, Åsa K, Wiltfang, Jens, Wolk, David A, Boada, Merce, Yen, Tzu-Chen, Zboch, Marzena, Zetterberg, Henrik, Boecker, Henning, Tijms, Betty M, Bottlaender, Michel, den Braber, Anouk, Brooks, David J, Van Buchem, Mark A, Camus, Vincent, Carill, Jose Manuel, Cerman, Jiri, Chen, Kewei, Chételat, Gaël, Chipi, Elena, Vos, Stephanie J B, Cohen, Ann D, Daniels, Alisha, Delarue, Marion, Didic, Mira, Drzezga, Alexander, Dubois, Bruno, Eckerström, Marie, Ekblad, Laura L, Engelborghs, Sebastiaan, Epelbaum, Stéphane, Ossenkoppele, Rik, Fagan, Anne M, Fan, Yong, Fladby, Tormod, Fleisher, Adam S, Van der Flier, Wiesje M, Förster, Stefan, Fortea, Juan, Frederiksen, Kristian Steen, Freund-Levi, Yvonne, Frings, Lars, Visser, Pieter Jelle, Frisoni, Giovanni B, Fröhlich, Lutz, Gabryelewicz, Tomasz, Gertz, Hermann-Josef, Gill, Kiran Dip, Gkatzima, Olymbia, Gómez-Tortosa, Estrella, Grimmer, Timo, Guedj, Eric, Habeck, Christian G, Group, Amyloid Biomarker Study, Hampel, Harald, Handels, Ron, Hansson, Oskar, Hausner, Lucrezia, Hellwig, Sabine, Heneka, Michael, Herukka, Sanna-Kaisa, Hildebrandt, Helmut, Hodges, John, Hort, Jakub, Aarsland, Dag, Huang, Chin-Chang, Iriondo, Ane Juaristi, Itoh, Yoshiaki, Ivanoiu, Adrian, Jagust, William J, Jessen, Frank, Johannsen, Peter, Johnson, Keith A, Kandimalla, Ramesh, Kapaki, Elisabeth N, Alcolea, Daniel, Kern, Silke, Kilander, Lena, Klimkowicz-Mrowiec, Aleksandra, Klunk, William E, Koglin, Norman, Kornhuber, Johannes, Kramberger, Milica G, Kuo, Hung-Chou, Van Laere, Koen, Landau, Susan M, Altomare, Daniele, Landeau, Brigitte, Lee, Dong Young, de Leon, Mony, Leyton, Cristian E, Lin, Kun-Ju, Lleó, Alberto, Löwenmark, Malin, Madsen, Karine, Maier, Wolfgang, Marcusson, Jan, Clinical sciences, Neuroprotection & Neuromodulation, Neurology, Amsterdam Neuroscience - Brain Imaging, Amsterdam Neuroscience - Neurodegeneration, Radiology and nuclear medicine, Laboratory Medicine, Amsterdam Neuroscience - Neuroinfection & -inflammation, APH - Personalized Medicine, APH - Methodology, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, and Psychiatrie & Neuropsychologie
- Subjects
Male ,MILD COGNITIVE IMPAIRMENT ,epidemiology [Cognitive Dysfunction] ,positron emission tomography ,Alzheimer`s disease Donders Center for Medical Neuroscience [Radboudumc 1] ,epidemiology [Alzheimer Disease] ,Neuroscience(all) ,diagnostic imaging [Cognitive Dysfunction] ,Amyloidogenic Proteins ,tau Proteins ,cerebrospinal fluid [Amyloid beta-Peptides] ,DIAGNOSIS ,cerebrospinal fluid ,Apolipoproteins E ,Alzheimer Disease ,Prevalence ,Humans ,Amyloid, Alzheimer, PET ,Cognitive Dysfunction ,ddc:610 ,cerebrospinal fluid [Peptide Fragments] ,Aged ,Amyloid beta-Peptides ,neurology ,DEMENTIA ,Correction ,ASSOCIATION ,Amyloidosis ,Middle Aged ,Disorders of movement Donders Center for Medical Neuroscience [Radboudumc 3] ,health care planning ,clinical trial design ,Peptide Fragments ,cerebrospinal fluid [Alzheimer Disease] ,PET ,DRIFT ,Cross-Sectional Studies ,cerebrospinal fluid [Biomarkers] ,cerebrospinal fluid [tau Proteins] ,Radiology Nuclear Medicine and imaging ,Positron-Emission Tomography ,genetics [Apolipoproteins E] ,Female ,Neurology (clinical) ,diagnostic imaging [Alzheimer Disease] ,cerebral amyloid aggregation ,Biomarkers - Abstract
Importance: One characteristic histopathological event in Alzheimer disease (AD) is cerebral amyloid aggregation, which can be detected by biomarkers in cerebrospinal fluid (CSF) and on positron emission tomography (PET) scans. Prevalence estimates of amyloid pathology are important for health care planning and clinical trial design.Objective: To estimate the prevalence of amyloid abnormality in persons with normal cognition, subjective cognitive decline, mild cognitive impairment, or clinical AD dementia and to examine the potential implications of cutoff methods, biomarker modality (CSF or PET), age, sex, APOE genotype, educational level, geographical region, and dementia severity for these estimates.Design, Setting, and Participants: This cross-sectional, individual-participant pooled study included participants from 85 Amyloid Biomarker Study cohorts. Data collection was performed from January 1, 2013, to December 31, 2020. Participants had normal cognition, subjective cognitive decline, mild cognitive impairment, or clinical AD dementia. Normal cognition and subjective cognitive decline were defined by normal scores on cognitive tests, with the presence of cognitive complaints defining subjective cognitive decline. Mild cognitive impairment and clinical AD dementia were diagnosed according to published criteria.Exposures: Alzheimer disease biomarkers detected on PET or in CSF.Main Outcomes and Measures: Amyloid measurements were dichotomized as normal or abnormal using cohort-provided cutoffs for CSF or PET or by visual reading for PET. Adjusted data-driven cutoffs for abnormal amyloid were calculated using gaussian mixture modeling. Prevalence of amyloid abnormality was estimated according to age, sex, cognitive status, biomarker modality, APOE carrier status, educational level, geographical location, and dementia severity using generalized estimating equations.Results: Among the 19 097 participants (mean [SD] age, 69.1 [9.8] years; 10 148 women [53.1%]) included, 10 139 (53.1%) underwent an amyloid PET scan and 8958 (46.9%) had an amyloid CSF measurement. Using cohort-provided cutoffs, amyloid abnormality prevalences were similar to 2015 estimates for individuals without dementia and were similar across PET- and CSF-based estimates (24%; 95% CI, 21%-28%) in participants with normal cognition, 27% (95% CI, 21%-33%) in participants with subjective cognitive decline, and 51% (95% CI, 46%-56%) in participants with mild cognitive impairment, whereas for clinical AD dementia the estimates were higher for PET than CSF (87% vs 79%; mean difference, 8%; 95% CI, 0%-16%; P = .04). Gaussian mixture modeling-based cutoffs for amyloid measures on PET scans were similar to cohort-provided cutoffs and were not adjusted. Adjusted CSF cutoffs resulted in a 10% higher amyloid abnormality prevalence than PET-based estimates in persons with normal cognition (mean difference, 9%; 95% CI, 3%-15%; P = .004), subjective cognitive decline (9%; 95% CI, 3%-15%; P = .005), and mild cognitive impairment (10%; 95% CI, 3%-17%; P = .004), whereas the estimates were comparable in persons with clinical AD dementia (mean difference, 4%; 95% CI, -2% to 9%; P = .18).Conclusions and Relevance: This study found that CSF-based estimates using adjusted data-driven cutoffs were up to 10% higher than PET-based estimates in people without dementia, whereas the results were similar among people with dementia. This finding suggests that preclinical and prodromal AD may be more prevalent than previously estimated, which has important implications for clinical trial recruitment strategies and health care planning policies.
- Published
- 2022
23. Best Practice Guidance on Human interaction with technology in dementia and conclusion
- Author
-
Dröes, RM, Orrell, Martin, Verhey, Frans R. J., d'Oliveira, Deborah, McDermott, Orii, Verhey, Frans, Dassen, Fania, Dröes, Rose-Marie, Psychiatry, APH - Mental Health, and APH - Aging & Later Life
- Published
- 2022
24. Additional file 2 of Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
- Author
-
Visser, Pieter Jelle, Reus, Lianne M., Gobom, Johan, Jansen, Iris, Dicks, Ellen, van der Lee, Sven J., Tsolaki, Magda, Verhey, Frans R. J., Popp, Julius, Martinez-Lage, Pablo, Vandenberghe, Rik, Lleó, Alberto, Molinuevo, José Luís, Engelborghs, Sebastiaan, Freund-Levi, Yvonne, Froelich, Lutz, Sleegers, Kristel, Dobricic, Valerija, Lovestone, Simon, Streffer, Johannes, Vos, Stephanie J. B., Bos, Isabelle, Smit, August B., Blennow, Kaj, Scheltens, Philip, Teunissen, Charlotte E., Bertram, Lars, Zetterberg, Henrik, and Tijms, Betty M.
- Subjects
mental disorders ,sense organs - Abstract
Additional file 2: Figure S1. Longitudinal change in CSF total tau. Figure S2. Enrichment of synaptic processes in individuals with AD according to t-tau status. Figure S3. Enriched GO biological processes and SUZ12 and REST transcription factors associated with proteins that differed between AD individuals with increased t-tau and normal t-tau and proteins that changed with disease severity.
- Published
- 2022
- Full Text
- View/download PDF
25. Characteristics of subjective cognitive decline associated with amyloid positivity
- Author
-
Janssen, Olin, Jansen, Willemijn J, Epelbaum, Stéphane, Lleó, Alberto, Engelborghs, Sebastiaan, van der Flier, Wiesje M, Landau, Susan, Popp, Julius, Wallin, Anders, Scheltens, Philip, Rikkert, Marcel Olde, Snyder, Peter J, Vos, Stephanie J B, Rowe, Chris, Chételat, Gaël, Ruíz, Agustin, Marquié, Marta, Chipi, Elena, Wolfsgruber, Steffen, Heneka, Michael, Boecker, Henning, Peters, Oliver, Jarholm, Jonas, Boada, Merce, Rami, Lorena, Tort-Merino, Adrià, Binette, Alexa Pichet, Poirier, Judes, Rosa-Neto, Pedro, Cerman, Jiri, Dubois, Bruno, Teichmann, Marc, Alcolea, Daniel, Fortea, Juan, Parnetti, Lucilla, Sánchez-Saudinós, M Belén, Ebenau, Jarith, Pocnet, Cornelia, Eckerström, Marie, Thompson, Louisa, Villemagne, Victor, Buckley, Rachel, Burnham, Samantha, Delarue, Marion, Freund-Levi, Yvonne, Gabryelewicz, Tomasz, Wallin, Åsa K, Ramakers, Inez, Tsolaki, Magda, Soininen, Hilkka, Hampel, Harald, Spiru, Luiza, Initiative, Alzheimer's Disease Neuroimaging, group, FACEHBI study, group, PREVENT-AD research, Tijms, Betty, Fladby, Tormod, Ossenkoppele, Rik, Verhey, Frans R J, Jessen, Frank, Visser, Pieter Jelle, Molinuevo, José Luis, Villeneuve, Sylvia, Hort, Jakub, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Psychiatrie & Neuropsychologie, Neurology, Amsterdam Neuroscience - Neurodegeneration, Amsterdam Neuroscience - Brain Imaging, Alzheimers Dis Neuroimaging Initia, Facehbi Study Grp, PREVENT-AD Res Grp, Clinical sciences, and Neuroprotection & Neuromodulation
- Subjects
PRECLINICAL ALZHEIMERS-DISEASE ,Amyloid ,SYMPTOMS ,positron emission tomography ,Epidemiology ,Neuroscience(all) ,Apolipoprotein E4 ,Amyloidogenic Proteins ,cerebrospinal fluid ,Cellular and Molecular Neuroscience ,Developmental Neuroscience ,mental disorders ,Humans ,Cognitive Dysfunction ,ddc:610 ,DEPOSITION ,OLDER-ADULTS ,genetics [Apolipoprotein E4] ,POPULATION ,RISK ,neurology ,Health Policy ,DEMENTIA ,genetics [Cognitive Dysfunction] ,Brain ,amyloid ,Amyloidosis ,Alzheimer's disease ,PREVALENCE ,COMMUNITY ,Psychiatry and Mental health ,metabolism [Brain] ,Positron-Emission Tomography ,Neurology (clinical) ,Human medicine ,psychology [Cognitive Dysfunction] ,Geriatrics and Gerontology ,subjective cognitive decline ,MEMORY COMPLAINTS ,Biomarkers - Abstract
Introduction The evidence for characteristics of persons with subjective cognitive decline (SCD) associated with amyloid positivity is limited. Methods In 1640 persons with SCD from 20 Amyloid Biomarker Study cohort, we investigated the associations of SCD-specific characteristics (informant confirmation, domain-specific complaints, concerns, feelings of worse performance) demographics, setting, apolipoprotein E gene (APOE) epsilon 4 carriership, and neuropsychiatric symptoms with amyloid positivity. Results Between cohorts, amyloid positivity in 70-year-olds varied from 10% to 76%. Only older age, clinical setting, and APOE epsilon 4 carriership showed univariate associations with increased amyloid positivity. After adjusting for these, lower education was also associated with increased amyloid positivity. Only within a research setting, informant-confirmed complaints, memory complaints, attention/concentration complaints, and no depressive symptoms were associated with increased amyloid positivity. Feelings of worse performance were associated with less amyloid positivity at younger ages and more at older ages. Discussion Next to age, setting, and APOE epsilon 4 carriership, SCD-specific characteristics may facilitate the identification of amyloid-positive individuals.
- Published
- 2022
26. Anxiety and cognitive functioning in the Maastricht study: A cross-sectional population study
- Author
-
Gulpers, Bernice J. A., Verhey, Frans R. J., Eussen, Simone J. P. M., Schram, M.T., Galan, B.E. de, Boxtel, Martin P. J. van, Stehouwer, Coen D. A., Kohler, S., RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Psychiatrie & Neuropsychologie, RS: CAPHRI - R5 - Optimising Patient Care, Epidemiologie, MUMC+: HVC Pieken Maastricht Studie (9), RS: Carim - V01 Vascular complications of diabetes and metabolic syndrome, Interne Geneeskunde, Psychology 2, Section Neuropsychology, RS: FPN NPPP I, MUMC+: MA Interne Geneeskunde (3), and Psychology 5
- Subjects
Psychiatry and Mental health ,Clinical Psychology ,All institutes and research themes of the Radboud University Medical Center ,Cross-Sectional Studies ,Cognition ,Diabetes Mellitus, Type 2 ,Humans ,Metabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6] ,Anxiety ,Anxiety Disorders ,Aged - Abstract
BACKGROUND: Higher anxiety levels in older adults are associated with worse executive functioning and an increased risk for dementia. In this study individual anxiety disorders and clinically relevant generalized anxiety symptoms are studied in relation to multiple cognitive domains.METHOD: This cross-sectional study includes 7344 community-dwelling participants of The Maastricht Study aged 40-75 years and oversampling of type 2 diabetes. Panic disorder with and without agoraphobia, agoraphobia and lifetime panic disorder were measured with the Mini International Neuropsychiatric Interview. Generalized anxiety symptoms were measured with the Generalized Anxiety Disorder 7-item scale (GAD-7). Multiple cognitive domains (executive functioning, memory and processing speed) and cognitive impairment were assessed. Multivariable linear and logistic regression analyses were used with adjustment for potential confounders. Interaction analyses were performed to test the moderation of age, sex and type 2 diabetes (due to oversampling).RESULTS: Agoraphobia was associated with worse scores on all cognitive domains (range B = -0.12 to -0.10; range 95%CI = -0.20 to -0.04) and with higher odds of cognitive impairment (OR = 1.51, 95%CI = 1.18-1.93). High scores on the GAD-7 were associated with worse scores on processing speed (B = -0.11, 95%CI = -0.20 to -0.03) and higher odds of cognitive impairment (OR = 1.42, 95%CI = 1.02-1.97). Panic disorder was significantly associated with worse scores on memory tasks (B = -0.25, 95%CI = -0.48 to -0.02). Associations were stronger in the younger participants and for agoraphobia and GAD-7 scores also in those with type 2 diabetes.CONCLUSION: Multiple anxiety disorders and generalized anxiety symptoms were associated with worse cognitive functioning on several cognitive domains.
- Published
- 2021
27. The relation of depression with structural brain abnormalities and cognitive functioning: the Maastricht study.
- Author
-
Geraets, Anouk F. J., Schram, Miranda T., Jansen, Jacobus F. A., Koster, Annemarie, Dagnelie, Pieter C., van Greevenbroek, Marleen M. J., Stehouwer, Coen D. A., Verhey, Frans R. J., and Köhler, Sebastian
- Subjects
BRAIN anatomy ,BRAIN ,COGNITION disorders ,CEREBRAL small vessel diseases ,CEREBRAL hemorrhage ,CROSS-sectional method ,MULTIPLE regression analysis ,LACUNAR stroke ,MAGNETIC resonance imaging ,ATROPHY ,MENTAL depression ,DESCRIPTIVE statistics ,LOGISTIC regression analysis ,ODDS ratio - Abstract
Background: Individuals with depression often experience widespread and persistent cognitive deficits, which might be due to brain atrophy and cerebral small vessel disease (CSVD). We therefore studied the associations between depression, markers of brain atrophy and CSVD, and cognitive functioning. Methods: We used cross-sectional data from the population-based Maastricht study (n = 4734; mean age 59.1 ± 8.6 years, 50.2% women), which focuses on type 2 diabetes. A current episode of major depressive disorder (MDD, n = 151) was assessed by the Mini-International Neuropsychiatric Interview. Volumes of cerebral spinal fluid, white matter, gray matter and white matter hyperintensities, presence of lacunar infarcts and cerebral microbleeds, and total CSVD burden were assessed by 3 T magnetic resonance imaging. Multiple linear and logistic regression analyses tested the associations between MDD, brain markers and cognitive functioning in memory, information processing speed, and executive functioning & attention, and presence of cognitive impairment. Structural equation modeling was used to test mediation. Results: In fully adjusted models, MDD was associated with lower scores in information processing speed [mean difference = −0.18(−0.28;−0.08)], executive functioning & attention [mean difference = −0.13(−0.25;−0.02)], and with higher odds of cognitive impairment [odds ratio (OR) = 1.60(1.06;2.40)]. MDD was associated with CSVD in participants without type 2 diabetes [OR = 1.65(1.06;2.56)], but CSVD or other markers of brain atrophy or CSVD did not mediate the association with cognitive functioning. Conclusions: MDD is associated with more impaired information processing speed and executive functioning & attention, and overall cognitive impairment. Furthermore, MDD was associated with CSVD in participants without type 2 diabetes, but this association did not explain an impaired cognitive profile. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. A comparison of two approaches for modeling dementia progression in a changing patient context.
- Author
-
Wubben, Nina, Haaksma, Miriam, Ramakers, Inez H. G. B., van der Flier, Wiesje M., Verhey, Frans R. J., Olde Rikkert, Marcel G. M., and Melis, René J. F.
- Abstract
Objectives: To explain the heterogeneity in dementia disease trajectory, we studied the influence of changing patient characteristics on disease course by comparing the association of dementia progression with baseline comorbidity and frailty, and with time-varying comorbidity and frailty.Methods: We used individual growth models to study baseline and time-varying associations in newly diagnosed dementia patients (n = 331) followed for 3 years. We measured cognition using the Mini-Mental State Examination (MMSE), daily functioning using the Disability Assessment for Dementia (DAD), frailty using the Fried criteria and comorbidity using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G).Results: Although baseline comorbidity and frailty were associated with decreased daily functioning at diagnosis, their effects clearly diminished over time. In contrast, when incorporating comorbidity and frailty as time-varying covariates, comorbidity was associated with lower daily functioning, and frailty with both lower cognition and daily functioning. Being frail was associated with a 0.9-point lower MMSE score (p = 0.03) and a 14.9-point lower DAD score (p < 0.01). A 1-point increase in CIRS-G score was associated with a 1.1-point lower DAD score (p < 0.01).Conclusions: Time-varying comorbidity and frailty were more consistently associated with dementia disease course than baseline comorbidity and frailty. Therefore, modeling only baseline predictors is insufficient for understanding the course of dementia in a changing patient context. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
29. Cognitive changes in prevalent and incident cardiovascular disease: a 12-year follow-up in the Maastricht Aging Study (MAAS).
- Author
-
Schievink, Syenna H J, Boxtel, Martin P J van, Deckers, Kay, Oostenbrugge, Robert J van, Verhey, Frans R J, and Köhler, Sebastian
- Subjects
CARDIOVASCULAR diseases ,COGNITION ,DEMENTIA ,NEUROPSYCHOLOGY ,DISEASE management - Abstract
Aims Cardiovascular disease (CVD) has been suggested to accelerate cognitive decline and to be a risk factor for dementia, but still little is known about the cognitive course after a first cardiovascular event. Therefore, the present study aims to investigate the cognitive trajectories in both prevalent and incident CVD over a 12-year time period in the general population. Methods and results Cognitively healthy participants (age 24–82 years, n = 1823) of a prospective cohort study were serially assessed at baseline, 6 and 12 years. Verbal memory, executive function, and information processing speed were analysed in adults with prevalent, incident, and no CVD. Random effects models were used to test the association between CVD and change in cognitive function over time. At baseline, participants with prevalent CVD showed more decline in memory and information processing speed than healthy controls. Participants with incident CVD also showed more decline in these cognitive domains, but this was only significant in the follow-up period from 6 to 12 years. Associations were more pronounced in participants aged younger than 65 years at baseline, and in sub-analyses with angina pectoris or myocardial infarction as the most prevalent CVD conditions. Conclusion Prevalent and incident CVD predict cognitive decline in middle-aged individuals. Findings for incident CVD suggest that the onset of decline is linked in time with the vascular event itself. Timely CVD management may delay the onset of decline. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
30. Intervention mechanisms of an experience sampling intervention for spousal carers of people with dementia: a secondary analysis using momentary data.
- Author
-
Bartels, Sara Laureen, van Knippenberg, Rosalia J. M., Viechtbauer, Wolfgang, Simons, Claudia J. P., Ponds, Rudolf W., Myin-Germeys, Inez, Verhey, Frans R. J., and de Vugt, Marjolein E.
- Subjects
BEHAVIORAL assessment ,WELL-being ,LEISURE ,AFFECT (Psychology) ,BURDEN of care ,DEMENTIA patients ,SPOUSES ,RELAXATION for health ,TREATMENT effectiveness ,PSYCHOLOGY of caregivers ,DESCRIPTIVE statistics ,EMOTIONS ,STATISTICAL models ,PSYCHOTHERAPY ,BEHAVIOR modification ,HEALTH self-care ,SECONDARY analysis - Abstract
Objectives: A psychosocial intervention for spousal carers of people with dementia promoted emotional well-being through self-monitoring and personalized feedback, as demonstrated in a previous randomized controlled trial. The mechanism behind the intervention effects is thought to lie in increased awareness of, and thus, engagement in behaviours that elicit positive emotions (PA). This secondary analysis tests the assumption by investigating momentary data on activities, affect, and stress and explores the relevance of personalized feedback compared to self-monitoring only. Methods: The intervention was based on the experience sampling method (ESM), meaning that carers self-monitored own affect and behaviours 10 times/day over 6 weeks. The experimental group received personalized feedback on behaviours that elicit PA, while the pseudo-experimental group performed self-monitoring only. A control group was also included. ESM-data of 72 carers was analysed using multilevel mixed-effects models. Results: The experimental group reported significant increases in passive relaxation activities over the 6 weeks (B = 0.28, SE = 0.12, Z = 2.43, p <.05). Passive relaxation in this group was negatively associated with negative affect (r = –0.50, p =.01) and positively associated with activity-related stress (r = 0.52, p =.007) from baseline to post-intervention. Other activities in this or the other groups did not change significantly. Conclusion: Carer's daily behaviours were only affected when self-monitoring was combined with personalized feedback. Changing one's daily behaviour while caring for a person with dementia is challenging and aligned with mixed emotions. Acknowledging simultaneously positive and negative emotions, and feelings of stress is suggested to embrace the complexity of carer's life and provide sustainable support. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
31. Neuropsychological assessment and diagnostic disclosure at a memory clinic: A qualitative study of the experiences of patients and their family members.
- Author
-
Gruters, Angélique A. A., Christie, Hannah L., Ramakers, Inez H. G. B., Verhey, Frans R. J., Kessels, Roy P. C., and de Vugt, Marjolein E.
- Subjects
NEUROPSYCHOLOGICAL tests ,PATIENTS' attitudes ,PATIENT-family relations ,PATIENTS' families ,COGNITION disorders - Abstract
The aim of this study was to gain insight into the experiences of patients and their family members regarding a neuropsychological assessment (NPA) and the diagnostic disclosure given by the medical specialist (psychiatrist, geriatrician, or their residents) at the memory clinic (MC). Patients with and without a cognitive impairment and their family members were recruited from three Dutch MCs. Four focus groups with 14 patients and 13 family members were analyzed using both inductive and deductive content analysis. Three themes were identified: uncertainty, early diagnostic paradox, and knowledge utilization. High levels of uncertainty were experienced throughout the NPA and diagnostic disclosure. The early diagnostic paradox refers to the coexistence of negative emotions, feeling distressed due to undergoing an NPA that made them aware of their cognitive complaints, and the experience of relief due to insight given by the outcome of the NPA and medical diagnosis. Knowledge utilization refers to a low retention of medical information. Clinicians can reduce uncertainty by using clear communication, limiting interruptions during an NPA, and paying attention to contextual factors. Low information retention could possibly be improved by involving a family member and using visual aids or written information during the diagnostic disclosure. Finally, participants also appreciated being provided with neuropsychological feedback on the strengths and weaknesses of their cognitive profiles and with guidance on how to manage this diagnosis in their daily lives. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. Global Prevalence of Young-Onset Dementia: A Systematic Review and Meta-analysis.
- Author
-
Hendriks, Stevie, Peetoom, Kirsten, Bakker, Christian, van der Flier, Wiesje M., Papma, Janne M., Koopmans, Raymond, Verhey, Frans R. J., de Vugt, Marjolein, Köhler, Sebastian, Withall, Adrienne, Parlevliet, Juliette L., Uysal-Bozkir, Özgül, Gibson, Roger C., Neita, Susanne M., Nielsen, Thomas Rune, Salem, Lise C., Nyberg, Jenny, Lopes, Marcos Antonio, Dominguez, Jacqueline C., and De Guzman, Ma Fe
- Published
- 2021
- Full Text
- View/download PDF
33. Facing the Next "Geriatric Giant"-A Systematic Literature Review and Meta-Analysis of Interventions Tackling Loneliness and Social Isolation Among Older Adults.
- Author
-
Duffner LA, Janssen N, Deckers K, Schroyen S, de Vugt ME, Köhler S, Adam S, Verhey FRJ, and Veenstra MY
- Abstract
Objectives: Loneliness and social isolation are associated with adverse health outcomes, especially within the older adult population, underlining the need for effective interventions. This systematic review and meta-analysis aims to summarize all available evidence regarding the effectiveness of interventions for loneliness and social isolation, to map out their working mechanisms, and to give implications for policy and practice., Design: Systematic literature review and meta-analysis., Setting and Participants: Older adults (≥65 years)., Methods: A systematic search was conducted in MEDLINE, PsycINFO, and CINAHL for studies quantitively or qualitatively assessing effects of interventions for loneliness and social isolation in older adults, following predefined selection criteria. Risk of bias as well as small study effects were assessed and, wherever appropriate, information about effect sizes of individual studies pooled using random-effects meta-analyses. Sources for between-study heterogeneity were explored using meta-regression., Results: Of n = 2223 identified articles, n = 67 were eventually included for narrative synthesis. Significant intervention effects were reported for a proportion of studies (55.9% and 50.0% for loneliness and social isolation, respectively) and 57.6% of studies including a follow-up measure (n = 29) reported sustained intervention effects. Meta-analysis of n = 27 studies, representing n = 1756 participants, suggested a medium overall effect of loneliness interventions (d = -0.47; 95% CI, -0.62 to -0.32). Between-study heterogeneity was substantial and could not be explained by differences in study design, year of publication, outcome measures, intervention length, participant demographics, setting, baseline level of loneliness, or geographic location. However, non-technology-based interventions reported larger effect sizes on average (Δd = -0.35; 95% CI, -0.66 to -0.04; P = .029) and were more often significant. Qualitative assessment of potential intervention mechanisms resulted in 3 clusters of effective components: "promoting social contact," "transferring knowledge and skills," and "addressing social cognition"., Conclusions and Implications: Interventions for loneliness and social isolation can generally be effective, although some unexplained between-study heterogeneity remains. Further research is needed regarding the applicability of interventions across different settings and countries, also considering their cost-effectiveness., Competing Interests: Disclosure The authors declare no conflicts of interest., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
34. A Web-Based Intervention Based on Acceptance and Commitment Therapy for Family Caregivers of People With Dementia: Mixed Methods Feasibility Study.
- Author
-
Atefi GL, van Knippenberg RJM, Bartels SL, Losada-Baltar A, Márquez-González M, Verhey FRJ, and de Vugt ME
- Subjects
- Humans, Caregivers psychology, Feasibility Studies, Acceptance and Commitment Therapy, Internet-Based Intervention, Dementia therapy
- Abstract
Background: Acceptance and commitment therapy (ACT), as an empirically based third-wave cognitive behavioral therapy, has shown promise in enhancing well-being and functioning across diverse populations. However, in the context of caregiving, the effect size of available ACT interventions remains at best moderate, sometimes accompanied by high dropout rates, highlighting the need for more effective and feasible intervention designs., Objective: The objective of our study was to evaluate the feasibility and acceptability of a fully online ACT program designed for family caregivers of people with dementia. This study aimed to boost psychological flexibility and support caregivers, enabling them to realize and prioritize their own life values alongside their caregiving responsibilities., Methods: A mixed methods feasibility study using an uncontrolled pretest-posttest design was conducted. This intervention included a 9-week web-based self-help program based on ACT incorporating collaborative goal setting and weekly web-based motivational coaching for family caregivers of people with dementia. This study involved 30 informal caregivers recruited through memory clinics and social media platforms in the Netherlands and received approval from the Medical Ethics Committee of the Maastricht University Medical Center+ (NL77389.068.21/metc21-029)., Results: A total of 24 caregivers completed the postintervention assessment, indicating a high adherence rate (24/29, 83%). Caregivers reported positive feedback regarding collaborative goal setting, but some found challenges in implementing new skills due to their own habitual responses or the unpredictable context of dementia caregiving. Personalizing the intervention based on individual value preferences was highlighted as beneficial., Conclusions: Compared to other web-based self-help ACT interventions for family caregivers, this intervention showed a high adherence and sufficient level of feasibility, which underscores the use of personalization in delivering web-based interventions. Moreover, the potential of this ACT-based intervention for family caregivers of people with dementia was demonstrated, suggesting that further research and a larger-scale controlled trial are warranted to validate its effectiveness., International Registered Report Identifier (irrid): RR2-10.1136/bmjopen-2022-070499., (©Golnaz. L Atefi, Rosalia J M van Knippenberg, Sara Laureen Bartels, Andrés Losada-Baltar, María Márquez-González, Frans R J Verhey, Marjolein E de Vugt. Originally published in JMIR Aging (https://aging.jmir.org), 04.04.2024.)
- Published
- 2024
- Full Text
- View/download PDF
35. Relation of the kynurenine pathway with normal age: A systematic review.
- Author
-
Bakker L, Choe K, Eussen SJPM, Ramakers IHGB, van den Hove DLA, Kenis G, Rutten BPF, Verhey FRJ, and Köhler S
- Subjects
- Quinolinic Acid cerebrospinal fluid, Tryptophan metabolism, Kynurenine metabolism, Aging metabolism
- Abstract
Background: The kynurenine pathway (KP) is gaining more attention as a common pathway involved in age-related conditions. However, which changes in the KP occur due to normal ageing is still largely unclear. The aim of this systematic review was to summarize the available evidence for associations of KP metabolites with age., Methods: We used an broad search strategy and included studies up to October 2023., Results: Out of 8795 hits, 55 studies were eligible for the systematic review. These studies suggest that blood levels of tryptophan decrease with age, while blood and cerebrospinal fluid levels of kynurenine and its ratio with tryptophan increase. Studies investigating associations between cerebrospinal fluid and blood levels of kynurenic acid and quinolinic acid with age reported either positive or non-significant findings. However, there is a large heterogeneity across studies. Additionally, most studies were cross-sectional, and only few studies investigated associations with other downstream kynurenines., Conclusions: This systematic review suggests that levels of kynurenines are positively associated with age. Larger and prospective studies are needed that also investigate a more comprehensive panel of KP metabolites and changes during the life-course., Competing Interests: Declaration of Competing Interest The authors declare that they have no competing interests., (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
36. White Matter Hyperintensity Volume and Poststroke Cognition: An Individual Patient Data Pooled Analysis of 9 Ischemic Stroke Cohort Studies.
- Author
-
de Kort FAS, Coenen M, Weaver NA, Kuijf HJ, Aben HP, Bae HJ, Bordet R, Cammà G, Chen CPLH, Dewenter A, Duering M, Fang R, van der Giessen RS, Hamilton OKL, Hilal S, Huenges Wajer IMC, Kan CN, Kim J, Kim BJ, Köhler S, de Kort PLM, Koudstaal PJ, Lim JS, Lopes R, Mok VCT, Staals J, Venketasubramanian N, Verhagen CM, Verhey FRJ, Wardlaw JM, Xu X, Yu KH, Biesbroek JM, and Biessels GJ
- Subjects
- Humans, Female, Male, Brain diagnostic imaging, Brain pathology, Cognition, Cohort Studies, Magnetic Resonance Imaging, Infarction pathology, Neuropsychological Tests, Ischemic Stroke complications, White Matter diagnostic imaging, White Matter pathology, Brain Injuries pathology, Stroke complications, Stroke diagnostic imaging, Stroke pathology
- Abstract
Background: White matter hyperintensities (WMH) are associated with cognitive dysfunction after ischemic stroke. Yet, uncertainty remains about affected domains, the role of other preexisting brain injury, and infarct types in the relation between WMH burden and poststroke cognition. We aimed to disentangle these factors in a large sample of patients with ischemic stroke from different cohorts., Methods: We pooled and harmonized individual patient data (n=1568) from 9 cohorts, through the Meta VCI Map consortium (www.metavcimap.org). Included cohorts comprised patients with available magnetic resonance imaging and multidomain cognitive assessment <15 months poststroke. In this individual patient data meta-analysis, linear mixed models were used to determine the association between WMH volume and domain-specific cognitive functioning ( Z scores; attention and executive functioning, processing speed, language and verbal memory) for the total sample and stratified by infarct type. Preexisting brain injury was accounted for in the multivariable models and all analyses were corrected for the study site as a random effect., Results: In the total sample (67 years [SD, 11.5], 40% female), we found a dose-dependent inverse relationship between WMH volume and poststroke cognitive functioning across all 4 cognitive domains (coefficients ranging from -0.09 [SE, 0.04, P =0.01] for verbal memory to -0.19 [SE, 0.03, P <0.001] for attention and executive functioning). This relation was independent of acute infarct volume and the presence of lacunes and old infarcts. In stratified analyses, the relation between WMH volume and domain-specific functioning was also largely independent of infarct type., Conclusions: In patients with ischemic stroke, increasing WMH volume is independently associated with worse cognitive functioning across all major domains, regardless of old ischemic lesions and infarct type., Competing Interests: Disclosures Dr H.-J. Bae reports grants from Chong Gun Dang Pharmaceutical Corp and Korean Drug Co, Ltd outside of the submitted work. Dr G.J. Biessels reports grants from The Netherlands Organisation for Health Research and Development (ZonMW), during the conduct of the study. The other authors report no conflicts.
- Published
- 2023
- Full Text
- View/download PDF
37. The role of the kynurenine pathway in cognitive functioning after stroke: A prospective clinical study.
- Author
-
Bakker L, Ramakers IHGB, J P M Eussen S, Choe K, van den Hove DLA, Kenis G, Rutten BPF, van Oostenbrugge RJ, Staals J, Ulvik A, Ueland PM, Verhey FRJ, and Köhler S
- Subjects
- Male, Humans, Female, Prospective Studies, Biomarkers, Kynurenic Acid, Cognition, Kynurenine metabolism, Stroke complications
- Abstract
Background: The kynurenine pathway is the main metabolic pathway of tryptophan degradation and has been associated with stroke and impaired cognitive functioning, but studies on its role in post-stroke cognitive impairment (PSCI) are scarce. We aimed to investigate associations between metabolites of the kynurenine pathway at baseline and post-stroke cognitive functioning over time., Methods: Baseline plasma kynurenines were quantified in 198 stroke patients aged 65.4 ± 10.8 years, 138 (69.7%) men, who were followed up over a period of three years after stroke. Baseline and longitudinal associations of kynurenines with PSCI and cognitive domain scores were investigated using linear mixed models, adjusted for several confounders., Results: No evidence of associations between kynurenines and odds of PSCI were found. However, considering individual cognitive domains, higher plasma levels of anthranilic acid (AA) were associated with better episodic memory at baseline (β per SD 0.16 [0.05, 0.28]). Additionally, a linear-quadratic association was found for the kynurenic acid/ quinolinic acid ratio (KA/QA), a neuroprotective index, with episodic memory (Wald χ
2 = 8.27, p = .016). Higher levels of KA were associated with better processing speed in women only (pinteraction = .008; β per SD 0.15 [95% CI 0.02, 0.27]). These associations did not change over time., Conclusions: Higher levels of KA, AA and KA/QA were associated with better scores on some cognitive domains at baseline. These associations did not change over time. Given the exploratory nature and heterogeneity of findings, these results should be interpreted with caution, and verified in other prospective studies., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
38. The use of Acceptance and Commitment Therapy (ACT) in informal caregivers of people with dementia and other long-term or chronic conditions: A systematic review and conceptual integration.
- Author
-
Atefi GL, de Vugt ME, van Knippenberg RJM, Levin ME, Verhey FRJ, and Bartels SL
- Abstract
Informal caregivers are the primary source of support for adults with chronic conditions and disabilities. Empirical research highlights chronic stress and other risks of adverse outcomes of caregiving. Acceptance and Commitment Therapy (ACT) is an emerging evidenced-based practice that shows promise in improving an array of outcomes, theoretically by increasing psychological flexibility as the primary process of change. Research has begun to evaluate ACT among informal caregivers of adult populations, and a systematic review is now needed to summarise this evidence base. Electronic searches from five databases, including PubMed, PsycInfo, Embase, CINAHL, and Cochrane Library, yielded an initial 7896 hits, which after screening for inclusion criteria, resulted in 21 clinical trials. Studies were coded to synthesise the feasibility, effectiveness, and quality of evidence. Findings show that ACT was reported to be largely feasible and acceptable. However, the efficacy of ACT was mixed, with a more consistent pattern for informal caregivers of people with dementia. Several methodological quality issues limited the findings. However, theoretical synthesis and preliminary evidence support the promising effect of ACT in subgroups of informal caregivers. Research on the process of change, as well as larger-scale, methodologically rigorous trials, are needed to consolidate these findings., Competing Interests: Declaration of Competing Interest All authors declare that they have no conflicts of interest., (Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
39. Sex Differences in Poststroke Cognitive Impairment: A Multicenter Study in 2343 Patients With Acute Ischemic Stroke.
- Author
-
Exalto LG, Weaver NA, Kuijf HJ, Aben HP, Bae HJ, Best JG, Bordet R, Chen CPLH, van der Giessen RS, Godefroy O, Gyanwali B, Hamilton OKL, Hilal S, Huenges Wajer IMC, Kim J, Kappelle LJ, Kim BJ, Köhler S, de Kort PLM, Koudstaal PJ, Lim JS, Makin SDJ, Mok VCT, van Oostenbrugge RJ, Roussel M, Staals J, Valdés-Hernández MDC, Venketasubramanian N, Verhey FRJ, Wardlaw JM, Werring DJ, Xu X, van Zandvoort MJE, Biesbroek JM, Chappell FM, and Biessels GJ
- Abstract
Background: Poststroke cognitive impairment (PSCI) occurs in about half of stroke survivors. Cumulative evidence indicates that functional outcomes of stroke are worse in women than men. Yet it is unknown whether the occurrence and characteristics of PSCI differ between men and women., Methods: Individual patient data from 9 cohorts of patients with ischemic stroke were harmonized and pooled through the Meta-VCI-Map consortium (n=2343, 38% women). We included patients with visible symptomatic infarcts on computed tomography/magnetic resonance imaging and cognitive assessment within 15 months after stroke. PSCI was defined as impairment in ≥1 cognitive domains on neuropsychological assessment. Logistic regression analyses were performed to compare men to women, adjusted for study cohort, to obtain odds ratios for PSCI and individual cognitive domains. We also explored sensitivity and specificity of cognitive screening tools for detecting PSCI, according to sex (Mini-Mental State Examination, 4 cohorts, n=1814; Montreal Cognitive Assessment, 3 cohorts, n=278)., Results: PSCI was found in 51% of both women and men. Men had a lower risk of impairment of attention and executive functioning (men: odds ratio, 0.76 [95% CI, 0.61-0.96]), and language (men: odds ratio, 0.67 [95% CI, 0.45-0.85]), but a higher risk of verbal memory impairment (men: odds ratio, 1.43 [95% CI, 1.17-1.75]). The sensitivity of Mini-Mental State Examination (<25) for PSCI was higher for women (0.53) than for men (0.27; P =0.02), with a lower specificity for women (0.80) than men (0.96; P =0.01). Sensitivity and specificity of Montreal Cognitive Assessment (<26.) for PSCI was comparable between women and men (0.91 versus 0.86; P =0.62 and 0.29 versus 0.28; P =0.86, respectively)., Conclusions: Sex was not associated with PSCI occurrence but affected domains differed between men and women. The latter may explain why sensitivity of the Mini-Mental State Examination for detecting PSCI was higher in women with a lower specificity compared with men. These sex differences need to be considered when screening for and diagnosing PSCI in clinical practice.
- Published
- 2023
- Full Text
- View/download PDF
40. Correlations between kynurenines in plasma and CSF, and their relation to markers of Alzheimer's disease pathology.
- Author
-
Bakker L, Köhler S, Eussen SJPM, Choe K, van den Hove DLA, Kenis G, Rutten BPF, Ulvik A, Ueland PM, Verhey FRJ, and Ramakers IHGB
- Subjects
- Humans, Chromatography, Liquid, Neopterin, Cross-Sectional Studies, Prospective Studies, Tandem Mass Spectrometry, Tryptophan, tau Proteins cerebrospinal fluid, Amyloid beta-Peptides cerebrospinal fluid, Biomarkers, Kynurenine metabolism, Alzheimer Disease metabolism
- Abstract
Introduction: Altered levels of kynurenines in blood and cerebrospinal fluid (CSF) have been reported in Alzheimer's disease (AD). However, it is still largely unknown whether peripheral kynurenine concentrations resemble those found in CSF and how they relate to AD pathology. We therefore studied correlations between kynurenines in plasma and CSF and their associations with CSF amyloid-beta (Aβ
1-42 ) and tau levels in patients from the memory clinic spanning the whole cognitive spectrum., Methods: The Biobank Alzheimer Center Limburg study is a prospective cohort study of consecutive patients referred to the memory clinic of the Alzheimer Center Limburg. Plasma and CSF concentrations of tryptophan (TRP), eight kynurenines and neopterin from 138 patients were determined by means of LC-MS/MS. Additionally, CSF Aβ1-42 , total-tau (t-tau) and phosphorylated tau (p-tau) concentrations were determined using commercially available single-parameter ELISA methods. Partial correlations were used to analyze cross-sectional associations between kynurenines in plasma and CSF and their relation to AD related CSF-biomarkers adjusted for age, sex, educational level, and kidney function., Results: Moderate to strong correlations were observed between plasma and CSF levels for quinolinic acid (QA; r = 0.63), TRP (r = 0.47), anthranilic acid (r = 0.59), picolinic acid (r = 0.55), and the kynurenine (KYN)/TRP ratio (KTR; r = 0.55; all p < 0.0001), while other kynurenines correlated only weakly with their corresponding CSF values. No correlations were found between plasma and CSF levels of KA/QA. Several kynurenines were also weakly correlated with Aβ1-42 , t-tau or p-tau. Plasma levels of KA/QA were negatively correlated with Aβ1-42 (r = -0.21, p < 0.05). Plasma levels of TRP were negatively correlated with t-tau (r = -0.19) and levels of KYN with p-tau (r = -0.18; both p < 0.05). CSF levels of KYN (r = 0.20, p < 0.05), KA (r = 0.23, p < 0.01), and KTR (r = 0.18, p < 0.05) were positively correlated with Aβ1-42 . Finally, TRP and KYN were negatively (r = -0.22 and r = -0.18, respectively), and neopterin positively (r = 0.19) correlated with p-tau (all p < 0.05)., Conclusions: Plasma concentrations of TRP, KP metabolites, KTR, and neopterin all significantly correlated positively with their corresponding CSF concentrations, but many correlations were weak. Additionally, our results suggest a relation between higher kynurenine levels and lower AD pathology load. These results need verification in future studies and require more research into (shared) underlying mechanisms., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023. Published by Elsevier Inc.)- Published
- 2023
- Full Text
- View/download PDF
41. Corrigendum to "The cardiometabolic depression subtype and its association with clinical characteristics: The Maastricht Study" [J. Affect. Disord. 313 (2022) 110-117].
- Author
-
Geraets AFJ, Schram MT, Jansen JFA, Backes WH, Schalkwijk CG, Stehouwer CDA, van Boxtel MPJ, Eussen SJPM, Kooman JP, Verhey FRJ, and Köhler S
- Published
- 2023
- Full Text
- View/download PDF
42. Anxiety and cognitive functioning in the Maastricht study: A cross-sectional population study.
- Author
-
Gulpers BJA, Verhey FRJ, Eussen SJPM, Schram MT, de Galan BE, van Boxtel MPJ, Stehouwer CDA, and Köhler S
- Subjects
- Humans, Aged, Cross-Sectional Studies, Anxiety Disorders epidemiology, Cognition, Anxiety epidemiology, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 epidemiology
- Abstract
Background: Higher anxiety levels in older adults are associated with worse executive functioning and an increased risk for dementia. In this study individual anxiety disorders and clinically relevant generalized anxiety symptoms are studied in relation to multiple cognitive domains., Method: This cross-sectional study includes 7344 community-dwelling participants of The Maastricht Study aged 40-75 years and oversampling of type 2 diabetes. Panic disorder with and without agoraphobia, agoraphobia and lifetime panic disorder were measured with the Mini International Neuropsychiatric Interview. Generalized anxiety symptoms were measured with the Generalized Anxiety Disorder 7-item scale (GAD-7). Multiple cognitive domains (executive functioning, memory and processing speed) and cognitive impairment were assessed. Multivariable linear and logistic regression analyses were used with adjustment for potential confounders. Interaction analyses were performed to test the moderation of age, sex and type 2 diabetes (due to oversampling)., Results: Agoraphobia was associated with worse scores on all cognitive domains (range B = -0.12 to -0.10; range 95%CI = -0.20 to -0.04) and with higher odds of cognitive impairment (OR = 1.51, 95%CI = 1.18-1.93). High scores on the GAD-7 were associated with worse scores on processing speed (B = -0.11, 95%CI = -0.20 to -0.03) and higher odds of cognitive impairment (OR = 1.42, 95%CI = 1.02-1.97). Panic disorder was significantly associated with worse scores on memory tasks (B = -0.25, 95%CI = -0.48 to -0.02). Associations were stronger in the younger participants and for agoraphobia and GAD-7 scores also in those with type 2 diabetes., Conclusion: Multiple anxiety disorders and generalized anxiety symptoms were associated with worse cognitive functioning on several cognitive domains., Competing Interests: Conflict of Interest None for all authors., (Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
43. Characteristics of subjective cognitive decline associated with amyloid positivity.
- Author
-
Janssen O, Jansen WJ, Vos SJB, Boada M, Parnetti L, Gabryelewicz T, Fladby T, Molinuevo JL, Villeneuve S, Hort J, Epelbaum S, Lleó A, Engelborghs S, van der Flier WM, Landau S, Popp J, Wallin A, Scheltens P, Rikkert MO, Snyder PJ, Rowe C, Chételat G, Ruíz A, Marquié M, Chipi E, Wolfsgruber S, Heneka M, Boecker H, Peters O, Jarholm J, Rami L, Tort-Merino A, Binette AP, Poirier J, Rosa-Neto P, Cerman J, Dubois B, Teichmann M, Alcolea D, Fortea J, Sánchez-Saudinós MB, Ebenau J, Pocnet C, Eckerström M, Thompson L, Villemagne V, Buckley R, Burnham S, Delarue M, Freund-Levi Y, Wallin ÅK, Ramakers I, Tsolaki M, Soininen H, Hampel H, Spiru L, Tijms B, Ossenkoppele R, Verhey FRJ, Jessen F, and Visser PJ
- Subjects
- Humans, Amyloid, Amyloidogenic Proteins, Apolipoprotein E4 genetics, Biomarkers, Brain metabolism, Positron-Emission Tomography, Amyloidosis, Cognitive Dysfunction genetics, Cognitive Dysfunction psychology
- Abstract
Introduction: The evidence for characteristics of persons with subjective cognitive decline (SCD) associated with amyloid positivity is limited., Methods: In 1640 persons with SCD from 20 Amyloid Biomarker Study cohort, we investigated the associations of SCD-specific characteristics (informant confirmation, domain-specific complaints, concerns, feelings of worse performance) demographics, setting, apolipoprotein E gene (APOE) ε4 carriership, and neuropsychiatric symptoms with amyloid positivity., Results: Between cohorts, amyloid positivity in 70-year-olds varied from 10% to 76%. Only older age, clinical setting, and APOE ε4 carriership showed univariate associations with increased amyloid positivity. After adjusting for these, lower education was also associated with increased amyloid positivity. Only within a research setting, informant-confirmed complaints, memory complaints, attention/concentration complaints, and no depressive symptoms were associated with increased amyloid positivity. Feelings of worse performance were associated with less amyloid positivity at younger ages and more at older ages., Discussion: Next to age, setting, and APOE ε4 carriership, SCD-specific characteristics may facilitate the identification of amyloid-positive individuals., (© 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)
- Published
- 2022
- Full Text
- View/download PDF
44. The cardiometabolic depression subtype and its association with clinical characteristics: The Maastricht Study.
- Author
-
Geraets AFJ, Schram MT, Jansen JFA, Backes WH, Schalkwijk CG, Stehouwer CDA, van Boxtel MPJ, Eussen SJPM, Kooman JP, Verhey FRJ, and Köhler S
- Subjects
- Adult, Aged, Cohort Studies, Depression psychology, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Depressive Disorder, Major epidemiology, Metabolic Syndrome epidemiology, Metabolic Syndrome psychology
- Abstract
Background: Individuals with depression often show an adverse cardiometabolic risk profile and might represent a distinct depression subtype. The aim of this study was to investigate whether a cardiometabolic depression subtype could be identified and to investigate its association with demographics and clinical characteristics (severity, symptomatology, anti-depressant use, persistence and cognitive functioning)., Methods: We used data from The Maastricht Study, a population-based cohort in the southern part of The Netherlands. A total of 248 participants with major depressive disorder were included (mean [SD] age, 58.8 ± 8.5 years; 121 [48.8 %] were men). Major depressive disorder was assessed at baseline by the Mini-International Neuropsychiatric Interview. Cardiometabolic risk factors were defined as indicators of the metabolic syndrome according to the National Cholesterol Education Program Adult Treatment Panel III guidelines. We measured severity and persistence of depressive symptoms by use of the 9-item Patient Health Questionnaire., Results: Latent class analysis resulted in two subtypes, one with cardiometabolic depression (n = 145) and another with non-cardiometabolic depression (n = 103). The cardiometabolic depression subtype was characterized by being male, low education, more severe depressive symptoms, less symptoms of depressed mood and more symptoms of loss of energy, more use of antidepressant medication and lower cognitive functioning., Limitations: No conclusions can be made about causality., Conclusions: Latent class analysis suggested a distinct cardiometabolic depression subtype. Participants with cardiometabolic depression differed from participants with non-cardiometabolic depression in terms of demographics and clinical characteristics. The existence of a cardiometabolic depression subtype may indicate the need for prevention and treatment targeting cardiometabolic risk management., (Copyright © 2022. Published by Elsevier B.V.)
- Published
- 2022
- Full Text
- View/download PDF
45. Association Between Cognition, Health Related Quality of Life, and Costs in a Population at Risk for Cognitive Decline.
- Author
-
Janssen N, Handels RL, Wimo A, Antikainen R, Laatikainen T, Soininen H, Strandberg T, Tuomilehto J, Kivipelto M, Evers SMAA, Verhey FRJ, and Ngandu T
- Subjects
- Activities of Daily Living psychology, Cognition, Humans, Risk Factors, Cognitive Dysfunction epidemiology, Cognitive Dysfunction psychology, Quality of Life psychology
- Abstract
Background: The association between health-related quality of life (HRQoL) and care costs in people at risk for cognitive decline is not well understood. Studying this association could reveal the potential benefits of increasing HRQoL and reducing care costs by improving cognition., Objective: In this exploratory data analysis we investigated the association between cognition, HRQoL utilities and costs in a well-functioning population at risk for cognitive decline., Methods: An exploratory data analysis was conducted using longitudinal 2-year data from the FINGER study (n = 1,120). A change score analysis was applied using HRQoL utilities and total medical care costs as outcome. HRQoL utilities were derived from the Short Form Health Survey-36 (SF-36). Total care costs comprised visits to a general practitioner, medical specialist, nurse, and days at hospital. Analyses were adjusted for activities of daily living (ADL) and depressive symptoms., Results: Although univariable analysis showed an association between cognition and HRQoL utilities, multivariable analysis showed no association between cognition, HRQoL utilities and total care costs. A one-unit increase in ADL limitations was associated with a -0.006 (p < 0.001) decrease in HRQoL utilities and a one-unit increase in depressive symptoms was associated with a -0.004 (p < 0.001) decrease in HRQoL utilities., Conclusion: The level of cognition in people at-risk for cognitive decline does not seem to be associated with HRQoL utilities. Future research should examine the level at which cognitive decline starts to affect HRQoL and care costs. Ideally, this would be done by means of cross-validation in populations with various stages of cognitive functioning and decline.
- Published
- 2022
- Full Text
- View/download PDF
46. The Impact of Amyloid PET Disclosure on Quality of Life in Patients With Young Onset Dementia.
- Author
-
van der Doelen DM, Handels RLH, Zwan MD, van Kuijk SMJ, Pelkmans W, Bouwman FH, Scheltens P, Dirksen CD, and Verhey FRJ
- Subjects
- Amyloid, Disclosure, Humans, Positron-Emission Tomography methods, Alzheimer Disease diagnostic imaging, Quality of Life
- Abstract
Introduction: The impact of amyloid positron emission tomography (PET) imaging on patient health outcomes for individuals with dementia is unknown. In the present study, we explored the association between diagnostic outcome and clinician's level of certainty with quality of life (QoL) after [18F]flutemetamol PET results were disclosed in young onset dementia patients in a memory clinic cohort., Methods: In 154 patients suspected of dementia, QoL was measured before and after [18F]flutemetamol PET results were disclosed. Multiple regression analyses were conducted with (changed) general and disease-specific QoL measures as dependent factors [QoL-Alzheimer disease (AD) and EQ-5D Dutch tariff] and etiological diagnosis and clinician's certainty as independent factors., Results: (Change in) diagnosis of AD was associated to QOL in 2 of the 4 analyses (utility-based QoL β=0.15, P=0.010; disease-specific QoL β=2.0, P=0.037). Diagnostic certainty was associated to QOL in 1 of the 4 analyses (generic QoL β=0.002, P=0.028)., Discussion: The diverse results in this explorative analysis do not reflect a univocal association between diagnosis, certainty, and QoL. Nevertheless, this result could be interpreted as a possible potential for advanced diagnostic technologies for AD, which requires confirmation in future research., Competing Interests: The authors declare no conflicts of interest., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
47. Network impact score is an independent predictor of post-stroke cognitive impairment: A multicenter cohort study in 2341 patients with acute ischemic stroke.
- Author
-
Biesbroek JM, Weaver NA, Aben HP, Kuijf HJ, Abrigo J, Bae HJ, Barbay M, Best JG, Bordet R, Chappell FM, Chen CPLH, Dondaine T, van der Giessen RS, Godefroy O, Gyanwali B, Hamilton OKL, Hilal S, Huenges Wajer IMC, Kang Y, Kappelle LJ, Kim BJ, Köhler S, de Kort PLM, Koudstaal PJ, Kuchcinski G, Lam BYK, Lee BC, Lee KJ, Lim JS, Lopes R, Makin SDJ, Mendyk AM, Mok VCT, Oh MS, van Oostenbrugge RJ, Roussel M, Shi L, Staals J, Valdés-Hernández MDC, Venketasubramanian N, Verhey FRJ, Wardlaw JM, Werring DJ, Xin X, Yu KH, van Zandvoort MJE, Zhao L, and Biessels GJ
- Subjects
- Cohort Studies, Humans, Infarction complications, Cognitive Dysfunction complications, Ischemic Stroke complications, Stroke diagnosis
- Abstract
Background: Post-stroke cognitive impairment (PSCI) is a common consequence of stroke. Accurate prediction of PSCI risk is challenging. The recently developed network impact score, which integrates information on infarct location and size with brain network topology, may improve PSCI risk prediction., Aims: To determine if the network impact score is an independent predictor of PSCI, and of cognitive recovery or decline., Methods: We pooled data from patients with acute ischemic stroke from 12 cohorts through the Meta VCI Map consortium. PSCI was defined as impairment in ≥ 1 cognitive domain on neuropsychological examination, or abnormal Montreal Cognitive Assessment. Cognitive recovery was defined as conversion from PSCI < 3 months post-stroke to no PSCI at follow-up, and cognitive decline as conversion from no PSCI to PSCI. The network impact score was related to serial measures of PSCI using Generalized Estimating Equations (GEE) models, and to PSCI stratified according to post-stroke interval (<3, 3-12, 12-24, >24 months) and cognitive recovery or decline using logistic regression. Models were adjusted for age, sex, education, prior stroke, infarct volume, and study site., Results: We included 2341 patients with 4657 cognitive assessments. PSCI was present in 398/844 patients (47%) <3 months, 709/1640 (43%) at 3-12 months, 243/853 (28%) at 12-24 months, and 208/522 (40%) >24 months. Cognitive recovery occurred in 64/181 (35%) patients and cognitive decline in 26/287 (9%). The network impact score predicted PSCI in the univariable (OR 1.50, 95%CI 1.34-1.68) and multivariable (OR 1.27, 95%CI 1.10-1.46) GEE model, with similar ORs in the logistic regression models for specified post-stroke intervals. The network impact score was not associated with cognitive recovery or decline., Conclusions: The network impact score is an independent predictor of PSCI. As such, the network impact score may contribute to a more precise and individualized cognitive prognostication in patients with ischemic stroke. Future studies should address if multimodal prediction models, combining the network impact score with demographics, clinical characteristics and other advanced brain imaging biomarkers, will provide accurate individualized prediction of PSCI. A tool for calculating the network impact score is freely available at https://metavcimap.org/features/software-tools/lsm-viewer/., (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
48. The Role of Vascular Risk Factors in Biomarker-Based AT(N) Groups: A German-Dutch Memory Clinic Study.
- Author
-
Kučikienė D, Costa AS, Banning LCP, van Gils V, Schulz JB, Ramakers IHGB, Verhey FRJ, Vos SJB, and Reetz K
- Subjects
- Amyloid beta-Peptides cerebrospinal fluid, Atrophy, Biomarkers cerebrospinal fluid, Female, Humans, Male, Peptide Fragments cerebrospinal fluid, Risk Factors, tau Proteins cerebrospinal fluid, Alcoholism, Alzheimer Disease diagnostic imaging, Alzheimer Disease epidemiology, Alzheimer Disease pathology, Carotid Stenosis, Cognitive Dysfunction cerebrospinal fluid
- Abstract
Background: The relation between vascular risk factors (VRFs) and Alzheimer's disease (AD) is important due to possible pathophysiological association., Objective: To assess the prevalence of VRFs in biomarker-based AT(N) groups and the associations between VRFs, AD cerebrospinal fluid (CSF) biomarkers, brain magnetic resonance imaging (MRI), and cognition in clinical context., Methods: We included patients from two memory clinics in University Hospital Aachen (Germany) and Maastricht University Medical Centre (The Netherlands). Subjects were older than 45 years and had available data on demographics, VRFs, CSF AD biomarkers, and MRI. We categorized individuals in normal AD biomarkers, non-AD change, and AD-continuum groups based on amyloid (A), tau (T), and neurodegeneration (N) status in CSF and MRI. Regression models were corrected for age, sex, and site., Results: We included 838 participants (mean age 68.7, 53.2% male, mean MMSE 24.9). The most common VRFs were smoking (60.9%), hypertension (54.6%), and dyslipidemia (37.8%). Alcohol abuse and smoking were most frequent in the non-AD-change group, and coronary heart disease and carotid artery stenosis in the AD continuum group. Higher rates of depression were found in the normal AD biomarkers group. Parietal atrophy and cortical microbleeds were specific for the AD continuum group. Carotid artery stenosis was associated with pathological Aβ42 and T-tau values, and diabetes and alcohol abuse were associated with worse medial temporal atrophy and atrial fibrillation, with worse cognition., Conclusion: VRFs are common in memory clinic patients, showing differences across the AT(N) biomarker groups. This is important for prevention and individualized treatment of dementia.
- Published
- 2022
- Full Text
- View/download PDF
49. Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort.
- Author
-
Xu J, Green R, Kim M, Lord J, Ebshiana A, Westwood S, Baird AL, Nevado-Holgado AJ, Shi L, Hye A, Snowden SG, Bos I, Vos SJB, Vandenberghe R, Teunissen CE, Kate MT, Scheltens P, Gabel S, Meersmans K, Blin O, Richardson J, De Roeck EE, Engelborghs S, Sleegers K, Bordet R, Rami L, Kettunen P, Tsolaki M, Verhey FRJ, Alcolea D, Lleó A, Peyratout G, Tainta M, Johannsen P, Freund-Levi Y, Frölich L, Dobricic V, Frisoni GB, Molinuevo JL, Wallin A, Popp J, Martinez-Lage P, Bertram L, Blennow K, Zetterberg H, Streffer J, Visser PJ, Lovestone S, Proitsi P, Legido-Quigley C, and On Behalf Of The European Medical Information Framework Consortium
- Abstract
Background: physiological differences between males and females could contribute to the development of Alzheimer's Disease (AD). Here, we examined metabolic pathways that may lead to precision medicine initiatives., Methods: We explored whether sex modifies the association of 540 plasma metabolites with AD endophenotypes including diagnosis, cerebrospinal fluid (CSF) biomarkers, brain imaging, and cognition using regression analyses for 695 participants (377 females), followed by sex-specific pathway overrepresentation analyses, APOE ε4 stratification and assessment of metabolites' discriminatory performance in AD., Results: In females with AD, vanillylmandelate (tyrosine pathway) was increased and tryptophan betaine (tryptophan pathway) was decreased. The inclusion of these two metabolites (area under curve (AUC) = 0.83, standard error (SE) = 0.029) to a baseline model (covariates + CSF biomarkers, AUC = 0.92, SE = 0.019) resulted in a significantly higher AUC of 0.96 (SE = 0.012). Kynurenate was decreased in males with AD (AUC = 0.679, SE = 0.046)., Conclusions: metabolic sex-specific differences were reported, covering neurotransmission and inflammation pathways with AD endophenotypes. Two metabolites, in pathways related to dopamine and serotonin, were associated to females, paving the way to personalised treatment.
- Published
- 2021
- Full Text
- View/download PDF
50. Association of Type 2 Diabetes, According to the Number of Risk Factors Within Target Range, With Structural Brain Abnormalities, Cognitive Performance, and Risk of Dementia.
- Author
-
van Gennip ACE, Stehouwer CDA, van Boxtel MPJ, Verhey FRJ, Koster A, Kroon AA, Köhler S, van Greevenbroek MMJ, Wesselius A, Eussen SJPM, Backes WH, Jansen JF, Schram MT, Henry RMA, Singh-Manoux A, and van Sloten TT
- Subjects
- Brain, Cognition physiology, Humans, Magnetic Resonance Imaging methods, Prospective Studies, Risk Factors, Cognitive Dysfunction complications, Dementia complications, Dementia etiology, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 epidemiology
- Abstract
Objective: Type 2 diabetes is associated with increased risks of cognitive dysfunction and brain abnormalities. The extent to which risk factor modification can mitigate these risks is unclear. We investigated the associations between incident dementia, cognitive performance, and brain abnormalities among individuals with type 2 diabetes, according to the number of risk factors on target, compared with control subjects without diabetes., Research Design and Methods: Prospective data were from UK Biobank of 87,856 individuals ( n = 10,663 diabetes, n = 77,193 control subjects; baseline 2006-2010), with dementia follow-up until February 2018. Individuals with diabetes were categorized according to the number of seven selected risk factors within the guideline-recommended target range (nonsmoking; guideline-recommended levels of glycated hemoglobin, blood pressure, BMI, albuminuria, physical activity, and diet). Outcomes were incident dementia, domain-specific cognitive performance, white matter hyperintensities, and total brain volume., Results: After a mean follow-up of 9.0 years, 147 individuals (1.4%) with diabetes and 412 control subjects (0.5%) had incident dementia. Among individuals with diabetes, excess dementia risk decreased stepwise for a higher number of risk factors on target. Compared with control subjects (incidence rate per 1,000 person-years 0.62 [95% CI 0.56; 0.68]), individuals with diabetes who had five to seven risk factors on target had no significant excess dementia risk (absolute rate difference per 1,000 person-years 0.20 [-0.11; 0.52]; hazard ratio 1.32 [0.89; 1.95]). Similarly, differences in processing speed, executive function, and brain volumes were progressively smaller for a higher number of risk factors on target. These results were replicated in the Maastricht Study., Conclusions: Among individuals with diabetes, excess dementia risk, lower cognitive performance, and brain abnormalities decreased stepwise for a higher number of risk factors on target., (© 2021 by the American Diabetes Association.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.